NO970257D0 - Bestemmelse av tonisk ovarie-östrogen sekresjon i utvidede terapeutiske regimer - Google Patents

Bestemmelse av tonisk ovarie-östrogen sekresjon i utvidede terapeutiske regimer

Info

Publication number
NO970257D0
NO970257D0 NO970257A NO970257A NO970257D0 NO 970257 D0 NO970257 D0 NO 970257D0 NO 970257 A NO970257 A NO 970257A NO 970257 A NO970257 A NO 970257A NO 970257 D0 NO970257 D0 NO 970257D0
Authority
NO
Norway
Prior art keywords
determination
therapeutic regimens
estrogen secretion
extended therapeutic
tonic
Prior art date
Application number
NO970257A
Other languages
English (en)
Norwegian (no)
Other versions
NO970257L (no
Inventor
Gary D Hodgen
Audrey Philips
Original Assignee
Hampton Roads Medical College
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26959766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO970257(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/467,860 external-priority patent/US5658884A/en
Application filed by Hampton Roads Medical College, Ortho Pharma Corp filed Critical Hampton Roads Medical College
Publication of NO970257L publication Critical patent/NO970257L/no
Publication of NO970257D0 publication Critical patent/NO970257D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
NO970257A 1994-07-22 1997-01-21 Bestemmelse av tonisk ovarie-östrogen sekresjon i utvidede terapeutiske regimer NO970257D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27959394A 1994-07-22 1994-07-22
US08/467,860 US5658884A (en) 1994-07-22 1995-06-06 Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
PCT/US1995/008996 WO1996003138A1 (en) 1994-07-22 1995-07-18 Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens

Publications (2)

Publication Number Publication Date
NO970257L NO970257L (no) 1997-01-21
NO970257D0 true NO970257D0 (no) 1997-01-21

Family

ID=26959766

Family Applications (1)

Application Number Title Priority Date Filing Date
NO970257A NO970257D0 (no) 1994-07-22 1997-01-21 Bestemmelse av tonisk ovarie-östrogen sekresjon i utvidede terapeutiske regimer

Country Status (29)

Country Link
EP (1) EP0769956B1 (de)
JP (1) JP3138477B2 (de)
CN (1) CN1137722C (de)
AP (1) AP775A (de)
AT (1) ATE190494T1 (de)
AU (1) AU691952B2 (de)
BG (1) BG63363B1 (de)
BR (1) BR9508718A (de)
CA (1) CA2195745C (de)
CY (1) CY2228B1 (de)
CZ (1) CZ291803B6 (de)
DE (1) DE69515666T2 (de)
DK (1) DK0769956T3 (de)
EE (1) EE03515B1 (de)
ES (1) ES2145286T3 (de)
FI (1) FI970244L (de)
GR (1) GR3033590T3 (de)
HU (1) HU218910B (de)
IL (1) IL114655A (de)
IS (1) IS4413A (de)
LV (1) LV11823B (de)
MX (1) MX9700574A (de)
NO (1) NO970257D0 (de)
NZ (1) NZ290554A (de)
OA (1) OA10730A (de)
PT (1) PT769956E (de)
RU (1) RU2181598C2 (de)
SK (1) SK282118B6 (de)
WO (1) WO1996003138A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173592B1 (en) 1999-03-31 2012-05-08 Zentaris Ivf Gmbh Method for a programmed controlled ovarian stimulation protocol
PL201898B1 (pl) * 1999-09-23 2009-05-29 Zentaris Gmbh Zastosowanie antagonisty LH-RH w leczeniu endometriozy
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
GB0616111D0 (en) * 2006-06-16 2006-09-20 Ardana Bioscience Ltd Agents, methods and uses
EP2095818A1 (de) 2008-02-29 2009-09-02 AEterna Zentaris GmbH Verwendung von LHRH-Antagonisten in nicht-kastrierenden Dosen
EP2307040B1 (de) * 2008-05-29 2015-09-09 Isr Immune System Regulation Ab Gnrh und sexhormone zur behandlung von viruserkrankungen, insbesondere hiv/aids
AU2016264034B2 (en) * 2015-05-18 2020-03-05 KaNDy Therapeutics Limited Dual NK-1/NK-3 receptor antagonists for the treatment of sex-hormone-dependent diseases
EA202092131A1 (ru) 2018-03-14 2020-11-27 Кэнди Терапьютикс Лимитед Новый фармацевтический препарат, содержащий двойные антагонисты рецептора nk-1/nk-3
EP3560555A1 (de) 2018-04-26 2019-10-30 LifeArc Zusammensetzung zur behandlung einer oder mehrerer östrogenvermittelter krankheiten
US12533358B1 (en) 2025-05-14 2026-01-27 Bayer Consumer Care Ag Methods of treatment with elinzanetant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171835A (en) * 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
US5169932A (en) * 1989-10-30 1992-12-08 The Salk Institute For Biological Studies Gnrh analogs
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
US5681817A (en) * 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease

Also Published As

Publication number Publication date
CY2228B1 (en) 2003-04-18
IL114655A0 (en) 1995-11-27
FI970244A0 (fi) 1997-01-21
JP3138477B2 (ja) 2001-02-26
WO1996003138A1 (en) 1996-02-08
NZ290554A (en) 2000-08-25
PT769956E (pt) 2000-07-31
BG101158A (bg) 1997-09-30
SK7097A3 (en) 1997-11-05
EP0769956A4 (de) 1999-03-10
GR3033590T3 (en) 2000-09-29
AP775A (en) 1999-10-28
JPH10503203A (ja) 1998-03-24
FI970244A7 (fi) 1997-01-21
AU691952B2 (en) 1998-05-28
DE69515666T2 (de) 2000-07-06
CN1200674A (zh) 1998-12-02
BR9508718A (pt) 1997-12-30
ES2145286T3 (es) 2000-07-01
NO970257L (no) 1997-01-21
MX9700574A (es) 1997-12-31
OA10730A (en) 2001-06-07
ATE190494T1 (de) 2000-04-15
SK282118B6 (sk) 2001-11-06
FI970244L (fi) 1997-01-21
CN1137722C (zh) 2004-02-11
LV11823B (en) 1998-03-20
LV11823A (lv) 1997-08-20
HUT77127A (hu) 1998-03-02
AU3132095A (en) 1996-02-22
CA2195745C (en) 2005-03-29
CZ15097A3 (en) 1997-11-12
IS4413A (is) 1997-01-14
DE69515666D1 (de) 2000-04-20
CZ291803B6 (cs) 2003-06-18
IL114655A (en) 2005-08-31
HU218910B (hu) 2000-12-28
EE9700208A (et) 1998-02-16
EP0769956B1 (de) 2000-03-15
BG63363B1 (bg) 2001-11-30
HU9700046D0 (en) 1997-02-28
EP0769956A1 (de) 1997-05-02
CA2195745A1 (en) 1996-02-08
AP9700913A0 (en) 1997-01-31
EE03515B1 (et) 2001-10-15
DK0769956T3 (da) 2000-06-05
RU2181598C2 (ru) 2002-04-27

Similar Documents

Publication Publication Date Title
DE69609353D1 (de) In der therapie verwendbare chinolin- und chinazolinverbindungen
DE69505657D1 (de) Fluorcarbonetherhybriden enthaltende physiologich akzeptabele emulsionen und verwendungsverfahren
FI963513A7 (fi) Geenien rinnakkainen ilmentäminen in vivo
NO972125D0 (no) Hemmoroideblandinger og fremgangsmåte for anvendelse
FI972681A0 (fi) Kynsien sientenvastainen käsittely
EE03512B1 (et) Epinastiin kasutamiseks valude ravis
ID18679A (id) Penggunaan terapi lanjutan
FI953423L (fi) Temotsolomidin tehostaminen ihmisten kasvainsoluissa
DE4480717T1 (de) Tiefwasser-Übungs- und Therapiebecken
DK295190D0 (da) Kosmetik- og hudbehandlingssammensaetninger
NO970257L (no) Bestemmelse av tonisk ovarie-östrogen sekresjon i utvidede terapeutiske regimer
NO951825D0 (no) Vannbasert hårbehandlingspreparat og anvendelse av dette
FI964854L (fi) Hydroksitioasetamidien valmistus ja niiden käyttö bentsotiofeenien synteesissä
KR960033565U (ko) 지압 및 쑥뜸 겸용 지압구
LV11523A (lv) Domperidona pielietosana kardalgijas arstesana
LV10916A (lv) Metoklopramida lietosana kardalgijas arstesana
KR970044605U (ko) 냉동실의 급속냉동칸의 구조
KR950022785U (ko) 발바닥 지압의자
SE9604300D0 (sv) Therapeutical use and method
FIU970096U0 (fi) Allasmainen kiuas
SE8604881D0 (sv) Alkylglycerolernas effekt vid cancerterapi
FI904U1 (fi) I stomkonstruktioner anvaendbart foerbindningsdel
KR960004995U (ko) 높이조절이 가능한 곽티슈의 케이스
SE9302237D0 (sv) Uppblaasbart/uppumpningsbart och formeftergivligt haestsko-sulinlaegg
KR950008157U (ko) 다리의 미용 교정기

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
FC2A Withdrawal, rejection or dismissal of laid open patent application